A Phase 3 interventional study of Intravitreal aflibercept injection [IAI] and Sham in Nonproliferative Diabetic Retinopathy, sponsored by Regeneron Pharmaceuticals. Completed at 89 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-30.
Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing aflibercept in Diabetic Retinopathy — 2 open to participants now, 4 under way, none of them phase 3. aflibercept · Diabetic Retinopathy.
Among the 21 studies testing aflibercept in Diabetic Retinopathy, this one is the 2nd largest by enrollment, is one of 6 that started in 2016, is one of 3 in phase 3, and was the 8th registered.
779 studies on the registry are indexed under Diabetic Retinopathy; 143 are open to participants now.
Browse Diabetic Retinopathy studies →2 of the 21 studies testing aflibercept in Diabetic Retinopathy are open now, in 2 countries. Recruiting first, the newest first:
Retina Consultants of Orange County · Sites in United States
Ages 21+
Ahmad Zeeshan Jamil · Sites in Pakistan
Ages 40+
By country, each count listing its studies:
aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 92 Diabetic Retinopathy studies recruiting now, 60 (65%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 10 · Phase 3 5 · Phase 4 8
First in 2011; this study’s year is marked. 6 started in 2016.
This study's enrollment of 402 is above the median of 80 across 482 interventional studies indexed under Diabetic Retinopathy.
Median enrollment 38 across the 21 interventional studies. Of the 14 that completed or were terminated, 6 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 21 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Regeneron Pharmaceuticals has 6 studies filed under Diabetic Retinopathy — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing aflibercept in Diabetic Retinopathy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to assess the efficacy of intravitreal (IVT) aflibercept compared to sham treatment in the improvement of moderately severe to severe nonproliferative diabetic retinopathy (NPDR).
The secondary objectives of the study are:
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other inclusion/ exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive IVT aflibercept dosing regimen 1
Drug: Intravitreal aflibercept injection [IAI]
Participants will receive IVT aflibercept dosing regimen 2
Drug: Intravitreal aflibercept injection [IAI]
Participants will receive matching sham injections
Drug: Sham
Also known as: EYLEA® (aflibercept) Injection, BAY86-5321
Percentage of Participants Who Improved by ≥2 Steps From Baseline in the Diabetic Retinopathy Disease Severity Scale (DRSS) Score at Week 24 in the Combined 2Q16 and 2Q8 Groups
The Diabetic Retinopathy Disease Severity Scale (DRSS) may be used to describe overall retinopathy severity as well as the change in severity over time. Severity range from level 10 (DR absent) to level 85 (advanced proliferative DR: posterior fundus obscured, or center of macula detached). Here, DRSS describes severity level 47 (moderately severe NPDR) and level 53 (severe NPDR) at week 24 from baseline.
Time frame: At Week 24
Percentage of Participants With a ≥ 2-step Change at Week 52 in Diabetic Retinopathy Severity Scale (DRSS) From Baseline
The Diabetic Retinopathy Disease Severity Scale (DRSS) may be used to describe overall retinopathy severity as well as the change in severity over time. Severity range from level 10 (DR absent) to level 85 (advanced proliferative DR: posterior fundus obscured, or center of macula detached). Here, DRSS describes severity level 47 (moderately severe NPDR) and level 53 (severe NPDR) at week 52 from baseline.
Time frame: At Week 52
Percentage of Participants Who Developed a Vision-Threatening Complication Due to Diabetic Retinopathy at Week 52
Vision-threatening complications are defined as the composite outcome of proliferative diabetic retinopathy (PDR) (inclusive of participants who have vitreous hemorrhage or tractional retinal detachment believed to be due to PDR) and anterior segment neovascularization (ASNV) (participants with neovascularization of the iris \[at least 2 cumulative clock hours\], and/or definitive neovascularization of the iridocorneal angle).
Time frame: At Week 52
Percentage of Participants Who Developed Central Involved-Diabetic Macular Edema (CI-DME) at Week 52
The percentage of participants who developed CI-DME at week 52 were reported.
Time frame: At Week 52
Time to Development of Any Neovascular Vision Threatening Complication (PDR/ASNV) Through Week 52
Vision-threatening complication (VTC) is defined as the composite outcome of proliferative diabetic retinopathy (PDR) (inclusive of participants who have vitreous hemorrhage or tractional retinal detachment believed to be due to PDR) and anterior segment neovascularization (ASNV) (participants with neovascularization of the iris \[at least 2 cumulative clock hours\], and/or definitive neovascularization of the iridocorneal angle). Vision Threatening Complications include PDR/ASNV identified by investigators and Diabetic Retinopathy Scale Score (DRSS) \>61.
Time frame: Baseline through week 52 (day 365)
Time to Development of Central Involved-Diabetic Macular Edema (CI-DME) Through Week 52
Time to develop Central Involved-Diabetic Macular Edema (CI-DME) through week 52 reported.
Time frame: Baseline through week 52 (day 365)
Percentage of Participants Who Received Panretinal Photocoagulation (PRP), Inclusive of Participants Undergoing Vitrectomy With Endolaser, at Week 52
The percentage of participants who received panretinal photocoagulation (PRP), inclusive of participants undergoing vitrectomy with endolaser, at week 52 were reported.
Time frame: At Week 52
Area Under the Curve (AUC) for Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 52
The area under the curve (AUC) is the area under the best corrected visual acuity (BCVA) versus time curve from baseline to week 52. Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. BCVA scale range is 0 (worst) to 100 (best).
Time frame: At week 52
Recruitment for this study was conducted in the following countries between 29 Mar 2016 and 07 Aug 2017: Germany, Hungary, Japan, the United Kingdom, and the United States. A total of 759 participants were screened.
| Milestone | Sham Treatment | Intravitreal Aflibercept Injection (IAI) 2Q16 | Intravitreal Aflibercept Injection (IAI) 2Q8 |
|---|---|---|---|
| Started | 133 | 135 | 134 |
| Completed week 52 | 109 | 122 | 124 |
| Completed | 97 | 111 | 112 |
| Not completed | 36 | 24 | 22 |
| Withdrew: Adverse event | 4 | 9 | 0 |
| Withdrew: Death | 8 | 1 | 2 |
| Withdrew: Withdrawal by subject | 4 | 9 | 6 |
| Withdrew: Lost to follow-up | 18 | 5 | 14 |
| Withdrew: Protocol deviation | 1 | 0 | 0 |
| Withdrew: Pregnancy | 1 | 0 | 0 |
The Diabetic Retinopathy Disease Severity Scale (DRSS) may be used to describe overall retinopathy severity as well as the change in severity over time. Severity range from level 10 (DR absent) to level 85 (advanced proliferative DR: posterior fundus obscured, or center of macula detached). Here, DRSS describes severity level 47 (moderately severe NPDR) and level 53 (severe NPDR) at week 24 from baseline.
| Percentage of participants | Sham Treatment | Intravitreal Aflibercept Injection (IAI) 2Q16 | Intravitreal Aflibercept Injection (IAI) 2Q8 | IAI 2 mg Groups Combined (2Q16 & 2Q8) |
|---|---|---|---|---|
| Percentage of Participants Who Improved by ≥2 Steps From Baseline in the Diabetic Retinopathy Disease Severity Scale (DRSS) Score at Week 24 in the Combined 2Q16 and 2Q8 Groups | 6.0 | 61.5 | 55.2 | 58.4 |
The Diabetic Retinopathy Disease Severity Scale (DRSS) may be used to describe overall retinopathy severity as well as the change in severity over time. Severity range from level 10 (DR absent) to level 85 (advanced proliferative DR: posterior fundus obscured, or center of macula detached). Here, DRSS describes severity level 47 (moderately severe NPDR) and level 53 (severe NPDR) at week 52 from baseline.
| Percentage of participants | Sham Treatment | Intravitreal Aflibercept Injection (IAI) 2Q16 | Intravitreal Aflibercept Injection (IAI) 2Q8 |
|---|---|---|---|
| Percentage of Participants With a ≥ 2-step Change at Week 52 in Diabetic Retinopathy Severity Scale (DRSS) From Baseline | 15.0 | 65.2 | 79.9 |
Vision-threatening complications are defined as the composite outcome of proliferative diabetic retinopathy (PDR) (inclusive of participants who have vitreous hemorrhage or tractional retinal detachment believed to be due to PDR) and anterior segment neovascularization (ASNV) (participants with neovascularization of the iris \[at least 2 cumulative clock hours\], and/or definitive neovascularization of the iridocorneal angle).
| Percentage of participants | Sham Treatment | Intravitreal Aflibercept Injection (IAI) 2Q16 | Intravitreal Aflibercept Injection (IAI) 2Q8 |
|---|---|---|---|
| Percentage of Participants Who Developed a Vision-Threatening Complication Due to Diabetic Retinopathy at Week 52 | 20.3 | 3.7 | 3.0 |
The percentage of participants who developed CI-DME at week 52 were reported.
| Percentage of participants | Sham Treatment | Intravitreal Aflibercept Injection (IAI) 2Q16 | Intravitreal Aflibercept Injection (IAI) 2Q8 |
|---|---|---|---|
| Percentage of Participants Who Developed Central Involved-Diabetic Macular Edema (CI-DME) at Week 52 | 25.6 | 6.7 | 8.2 |
Vision-threatening complication (VTC) is defined as the composite outcome of proliferative diabetic retinopathy (PDR) (inclusive of participants who have vitreous hemorrhage or tractional retinal detachment believed to be due to PDR) and anterior segment neovascularization (ASNV) (participants with neovascularization of the iris \[at least 2 cumulative clock hours\], and/or definitive neovascularization of the iridocorneal angle). Vision Threatening Complications include PDR/ASNV identified by investigators and Diabetic Retinopathy Scale Score (DRSS) \>61.
| Days | Sham Treatment | Intravitreal Aflibercept Injection (IAI) 2Q16 | Intravitreal Aflibercept Injection (IAI) 2Q8 |
|---|---|---|---|
| Time to Development of Any Neovascular Vision Threatening Complication (PDR/ASNV) Through Week 52 | NA (371 to NA) | NA (NA to NA) | NA (NA to NA) |
Time to develop Central Involved-Diabetic Macular Edema (CI-DME) through week 52 reported.
| Days | Sham Treatment | Intravitreal Aflibercept Injection (IAI) 2Q16 | Intravitreal Aflibercept Injection (IAI) 2Q8 |
|---|---|---|---|
| Time to Development of Central Involved-Diabetic Macular Edema (CI-DME) Through Week 52 | NA (333 to NA) | NA (NA to NA) | NA (NA to NA) |
The percentage of participants who received panretinal photocoagulation (PRP), inclusive of participants undergoing vitrectomy with endolaser, at week 52 were reported.
| Percentage of participants | Sham Treatment | Intravitreal Aflibercept Injection (IAI) 2Q16 | Intravitreal Aflibercept Injection (IAI) 2Q8 |
|---|---|---|---|
| Percentage of Participants Who Received Panretinal Photocoagulation (PRP), Inclusive of Participants Undergoing Vitrectomy With Endolaser, at Week 52 | 6.8 | 0.7 | 0.7 |
The area under the curve (AUC) is the area under the best corrected visual acuity (BCVA) versus time curve from baseline to week 52. Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. BCVA scale range is 0 (worst) to 100 (best).
| scores on a scale | Sham Treatment | Intravitreal Aflibercept Injection (IAI) 2Q16 | Intravitreal Aflibercept Injection (IAI) 2Q8 |
|---|---|---|---|
| Area Under the Curve (AUC) for Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 52 | 0.5 ± 3.01 | 1.7 ± 3.50 | 1.3 ± 3.49 |
Collected over All Adverse Events (AEs) were collected from signature of the informed consent form up to week 100 regardless of seriousness or relationship to investigational product. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sham Treatment | 8/133 (6%) | 38/133 (28.6%) | 104/133 (78.2%) |
| Intravitreal Aflibercept Injection (IAI) 2Q16 | 1/135 (0.7%) | 38/135 (28.1%) | 104/135 (77%) |
| Intravitreal Aflibercept Injection (IAI) 2Q8 | 3/134 (2.2%) | 47/134 (35.1%) | 106/134 (79.1%) |
| IAI 2 mg Groups Combined (2Q16 & 2Q8) | 4/269 (1.5%) | 85/269 (31.6%) | 210/269 (78.1%) |
| Event | Sham Treatment | Intravitreal Aflibercept Injection (IAI) 2Q16 | Intravitreal Aflibercept Injection (IAI) 2Q8 | IAI 2 mg Groups Combined (2Q16 & 2Q8) |
|---|---|---|---|---|
| CellulitisInfections and infestations | 1/133 | 2/135 | 5/134 | 7/269 |
| Coronary artery diseaseCardiac disorders | 1/133 | 5/135 | 4/134 | 9/269 |
| OsteomyelitisInfections and infestations | 4/133 | 1/135 | 0/134 | 1/269 |
| Ischaemic strokeNervous system disorders | 3/133 | 0/135 | 0/134 | 0/269 |
| Cardiac failure congestiveCardiac disorders | 1/133 | 2/135 | 3/134 | 5/269 |
| PneumoniaInfections and infestations | 2/133 | 3/135 | 3/134 | 6/269 |
| SepsisInfections and infestations | 1/133 | 0/135 | 3/134 | 3/269 |
| DehydrationMetabolism and nutrition disorders | 1/133 | 0/135 | 3/134 | 3/269 |
| Acute kidney injuryRenal and urinary disorders | 2/133 | 1/135 | 3/134 | 4/269 |
| Visual acuity reduced Fellow EyeEye disorders | 1/133 | 0/135 | 3/134 | 3/269 |
| Event | Sham Treatment | Intravitreal Aflibercept Injection (IAI) 2Q16 | Intravitreal Aflibercept Injection (IAI) 2Q8 | IAI 2 mg Groups Combined (2Q16 & 2Q8) |
|---|---|---|---|---|
| Diabetic retinal oedema Study EyeEye disorders | 43/133 | 14/135 | 19/134 | 33/269 |
| HypertensionVascular disorders | 25/133 | 28/135 | 20/134 | 48/269 |
| Conjunctival haemorrhage Study EyeEye disorders | 8/133 | 18/135 | 25/134 | 43/269 |
| Diabetic retinal oedema Fellow EyeEye disorders | 19/133 | 17/135 | 23/134 | 40/269 |
| Diabetic retinopathy Study EyeEye disorders | 22/133 | 3/135 | 5/134 | 8/269 |
| Urinary tract infectionInfections and infestations | 16/133 | 12/135 | 11/134 | 23/269 |
| NasopharyngitisInfections and infestations | 15/133 | 11/135 | 11/134 | 22/269 |
| Diabetes mellitusMetabolism and nutrition disorders | 13/133 | 11/135 | 8/134 | 19/269 |
| Vitreous floaters Study EyeEye disorders | 3/133 | 7/135 | 13/134 | 20/269 |
| Diabetic retinopathy Fellow EyeEye disorders | 12/133 | 13/135 | 10/134 | 23/269 |
The full analysis set (FAS) included all randomized participants who received any study treatment as assigned at baseline (as randomized).
| Age, Continuous(Years) | Sham Treatment | Intravitreal Aflibercept Injection (IAI) 2Q16 | Intravitreal Aflibercept Injection (IAI) 2Q8 | Total |
|---|---|---|---|---|
| Mean | 55.8 ± 10.31 | 55.4 ± 11.13 | 55.8 ± 10.19 | 55.7 ± 10.53 |
| Sex: Female, Male(Participants) | Sham Treatment | Intravitreal Aflibercept Injection (IAI) 2Q16 | Intravitreal Aflibercept Injection (IAI) 2Q8 | Total |
|---|---|---|---|---|
| Female | 64 | 60 | 53 | 177 |
| Male | 69 | 75 | 81 | 225 |
| Ethnicity (NIH/OMB)(Participants) | Sham Treatment | Intravitreal Aflibercept Injection (IAI) 2Q16 | Intravitreal Aflibercept Injection (IAI) 2Q8 | Total |
|---|---|---|---|---|
| Hispanic or Latino | 74 | 97 | 93 | 264 |
| Not Hispanic or Latino | 58 | 37 | 41 | 136 |
| Unknown or Not Reported | 1 | 1 | 0 | 2 |
| Race (NIH/OMB)(Participants) | Sham Treatment | Intravitreal Aflibercept Injection (IAI) 2Q16 | Intravitreal Aflibercept Injection (IAI) 2Q8 | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 4 | 6 |
| Asian | 4 | 12 | 7 | 23 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 | 2 |
| Black or African American | 13 | 16 | 12 | 41 |
| White | 107 | 99 | 104 | 310 |
| More than one race | 0 | 1 | 1 | 2 |
| Unknown or Not Reported | 8 | 5 | 5 | 18 |
| Baseline Diabetic Retinopathy Severity Score (DRSS)(Participants) | Sham Treatment | Intravitreal Aflibercept Injection (IAI) 2Q16 | Intravitreal Aflibercept Injection (IAI) 2Q8 | Total |
|---|---|---|---|---|
| Level 47 (Moderately Severe) | 99 | 102 | 101 | 302 |
| Level 53 (Severe) | 34 | 33 | 33 | 100 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2016 to primary completion in Aug 2018, 28 months.
Results were first posted in Nov 2019, 1 year 3 months after primary completion.
Of 21 phase 3 interventional studies under Diabetic Retinopathy, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 41. This study's 28 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept